Quantbot Technologies LP Buys 112,567 Shares of DexCom, Inc. (NASDAQ:DXCM)

Quantbot Technologies LP grew its position in DexCom, Inc. (NASDAQ:DXCM) by 698.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 128,682 shares of the medical device company’s stock after acquiring an additional 112,567 shares during the quarter. Quantbot Technologies LP’s holdings in DexCom were worth $8,627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Taylor Frigon Capital Management LLC grew its stake in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after buying an additional 11,075 shares during the last quarter. Brooktree Capital Management bought a new position in DexCom in the third quarter worth about $683,000. National Pension Service grew its holdings in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Intact Investment Management Inc. acquired a new position in DexCom during the 3rd quarter valued at about $650,000. Finally, Waters Parkerson & CO. LLC boosted its stake in DexCom by 4.2% in the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after purchasing an additional 10,892 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $77.83 on Tuesday. The stock has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a price-to-earnings-growth ratio of 2.23 and a beta of 1.17. The stock’s fifty day simple moving average is $70.76 and its 200-day simple moving average is $88.93. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,431 shares of company stock valued at $399,319. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Robert W. Baird upped their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Sanford C. Bernstein upped their target price on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Barclays reduced their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.